OXSR1 Antibody

What are the recommended applications for OXSR1 antibodies in cellular research?

OXSR1 antibodies are validated for multiple applications with specific optimal dilutions for each technique:

The most consistently successful application is Western blot, where OXSR1 typically appears as a 58 kDa band. For reproducible results, each antibody should be titrated in your specific experimental system to determine optimal working concentrations .

How should OXSR1 antibodies be stored and handled to maintain reactivity?

For optimal preservation of OXSR1 antibody activity:

• Store at -20°C for long-term preservation

• Most formulations remain stable for one year after shipment when stored properly

• For antibodies in glycerol-containing buffers (usually 50% glycerol with PBS, pH 7.3), aliquoting is unnecessary for -20°C storage

• For working stocks, store at 4°C for short-term use (typically up to one month)

• Avoid repeated freeze-thaw cycles which can lead to protein denaturation and loss of binding activity

• Some preparations (e.g., 20μl sizes) may contain 0.1% BSA as a stabilizer

• Buffer composition typically includes PBS with 0.02% sodium azide and 50% glycerol at pH 7.3

When planning experiments, consider bringing the antibody to room temperature before use and centrifuging briefly to collect contents at the bottom of the tube.

What controls should be included when validating a new OXSR1 antibody?

Proper validation of OXSR1 antibodies requires multiple controls:

• Positive controls: Use cell lines with known OXSR1 expression (HEK-293, HeLa, Jurkat, U-251 cells) or human tissues (liver, testis) that consistently show OXSR1 expression .

• Negative controls:

  • Primary antibody omission

  • Isotype control (rabbit IgG for polyclonal antibodies)

  • Antigen blocking/competition assay using the immunizing peptide (particularly important for phospho-specific antibodies)

• Phosphorylation-specific validation (for phospho-OXSR1 antibodies):

  • Treatment with phosphatase to eliminate signal

  • Use of phosphomimetic or phospho-deficient mutants

  • Treatment with kinase inhibitors that affect OXSR1 phosphorylation state

• Knockdown/knockout validation: OXSR1 knockdown cell lines using siRNA or CRISPR-Cas9 technology should show reduced or absent signal

A rigorous validation includes documentation of antibody specificity, reproducibility across different sample preparations, and correlation with orthogonal detection methods.

How can phospho-specific OXSR1 (Thr185) antibodies be utilized to investigate WNK kinase signaling pathways?

Phospho-specific OXSR1 (Thr185) antibodies are valuable tools for monitoring the activation state of OXSR1 in the WNK-SPAK/OSR1 kinase cascade:

• Stimulus-response experiments: Monitor OXSR1 Thr185 phosphorylation following:

  • Osmotic stress (hypotonic or hypertonic conditions)

  • Treatment with WNK kinase activators

  • DNA damage induction (ATM/ATR pathway activation)

• Pathway inhibition studies: Combine with WNK kinase inhibitors (e.g., Compound B) to assess downstream effects on:

  • Ion cotransporter phosphorylation (NKCC1, NKCC2, NCC)

  • Cell volume regulation

  • Potassium flux during infection models

• Time-course analysis: Track the temporal dynamics of OXSR1 activation following specific stimuli, using Western blotting with phospho-OXSR1 (Thr185) antibodies at defined time intervals (0, 5, 15, 30, 60 minutes)

• Co-immunoprecipitation coupled with phospho-detection: Investigate the interaction between phosphorylated OXSR1 and downstream targets containing the RFXV recognition motif

The specificity of the phospho-antibody should be confirmed using appropriate controls, including dephosphorylation treatments and phospho-deficient OXSR1 mutants (T185A).

What are the considerations for using OXSR1 antibodies in infection and inflammation models?

Recent research has identified OXSR1 as a critical regulator of inflammasome activation and bacterial infection response. When investigating these pathways:

• Infection models:

  • OXSR1 expression is upregulated in Mycobacterium marinum and M. tuberculosis infections

  • OXSR1 knockdown reduces bacterial burden through increased inflammasome activation

  • Monitor both total OXSR1 and phospho-OXSR1 levels during infection time course

• Inflammasome activation assessment:

  • Use OXSR1 antibodies in combination with markers of inflammasome activation (NLRP3, cleaved IL-1β)

  • Include potassium efflux measurements alongside OXSR1 detection

  • Compare results between wild-type and OXSR1 knockdown/knockout models

• Species-specific considerations:

  • Different model organisms may show divergent OXSR1 regulation

  • Zebrafish oxsr1a and human OXSR1 show conserved immunomodulatory functions

  • Test antibody cross-reactivity when working with non-human species

• Tissue-specific expression patterns:

  • OXSR1 function may differ between immune cells and epithelial tissues

  • Use IHC with OXSR1 antibodies to map expression patterns in infected tissues

  • Consider dual staining with cell-type markers to identify OXSR1-expressing populations

When designing these experiments, controls should include infection with virulence-deficient bacterial strains (e.g., ∆ESX1 M. marinum) to distinguish pathogen-specific responses.

How can OXSR1 antibodies be multiplexed with other markers to study ion transport regulation?

Multiplexing OXSR1 antibodies with other markers enables comprehensive analysis of the ion transport regulation network:

• Multi-channel immunofluorescence strategies:

  • OXSR1 detection combined with ion cotransporters (NKCC1, NKCC2, KCC2, KCC3)

  • Co-staining with upstream regulators (WNK1, WNK4)

  • Inclusion of phospho-specific antibodies to detect activated forms

• Sequential immunostaining protocol:

  • First primary antibody application (e.g., anti-OXSR1)

  • Detection with fluorophore-conjugated secondary antibody

  • Blocking/stripping step

  • Second primary antibody application (e.g., anti-NKCC1)

  • Detection with differently-labeled secondary antibody

  • Nuclear counterstaining

• Sample preparation considerations:

  • For phospho-epitopes, rapid fixation is critical

  • Antigen retrieval methods differ between markers (TE buffer pH 9.0 for OXSR1, other buffers may be optimal for partner proteins)

  • Careful selection of antibody host species to avoid cross-reactivity in multiple labeling

• Quantitative co-localization analysis:

  • Use of software tools to quantify spatial relationships

  • Calculation of Pearson's correlation coefficient

  • Line scan analysis across cellular compartments

This approach can reveal functional relationships between OXSR1 and ion transporters in various physiological contexts.

What are the key differences between polyclonal and monoclonal OXSR1 antibodies in research applications?

The choice between polyclonal and monoclonal OXSR1 antibodies significantly impacts experimental outcomes:

For investigating multiple species, polyclonal antibodies may offer broader cross-reactivity. For highly specific detection of phosphorylated forms (e.g., pThr185), carefully validated phospho-specific monoclonal antibodies provide more reliable results .

How should sample preparation be optimized for detecting OXSR1 in different experimental systems?

Optimal sample preparation varies by application and cellular context:

• Western blot sample preparation:

  • Use RIPA or NP-40 buffer with phosphatase inhibitors (critical for phospho-OXSR1 detection)

  • Sonicate samples briefly to shear DNA and reduce viscosity

  • Heat samples at 95°C for 5 minutes in reducing Laemmli buffer

  • Load 20-30 μg of total protein per lane

• Immunohistochemistry optimization:

  • Fixation: 10% neutral buffered formalin (24-48 hours)

  • Antigen retrieval: TE buffer pH 9.0 as primary method

  • Alternative: citrate buffer pH 6.0 may be used

  • Section thickness: 4-5 μm optimal for OXSR1 detection

  • Blocking: 5% normal goat serum to reduce background

• Immunofluorescence preparation:

  • Fixation: 4% paraformaldehyde (10-15 minutes)

  • Permeabilization: 0.1% Triton X-100 (10 minutes)

  • Blocking: 1-2% BSA in PBS (30-60 minutes)

  • Primary antibody incubation: 1:50-1:500 dilution, overnight at 4°C

• Immunoprecipitation considerations:

  • Lysis buffer: 50 mM Tris pH 7.4, 150 mM NaCl, 1% NP-40 with protease/phosphatase inhibitors

  • Pre-clear lysate with protein A/G beads

  • Use 0.5-4.0 μg antibody per 1.0-3.0 mg protein lysate

  • Overnight incubation at 4°C with gentle rotation

For phospho-specific detection, rapid sample processing with immediate addition of phosphatase inhibitors is critical to preserve phosphorylation status.

What are the methodological considerations for using OXSR1 antibodies in specialized cell types?

Working with specialized cell types requires tailored approaches:

• Immune cells (e.g., THP-1 macrophages):

  • Differentiate with PMA before infection/stimulation

  • Include cytokine measurements (TNF-α, IL-1β) alongside OXSR1 detection

  • Consider flow cytometry for quantitative cellular analysis

  • Use cell-permeable potassium indicators to correlate with OXSR1 activity

• Renal epithelial cells:

  • Culture on permeable supports for polarized expression

  • Examine apical vs. basolateral distribution of OXSR1

  • Co-stain with nephron segment markers

  • Use hypotonic/hypertonic challenges to activate the WNK-OXSR1 pathway

• Neuronal cells:

  • Longer fixation times may be required (15-20 minutes)

  • Include neuronal markers (MAP2, NeuN) in co-staining protocols

  • Examine subcellular localization in soma vs. processes

  • Consider activity-dependent changes in OXSR1 phosphorylation

• T cells:

  • Activation with anti-CD3/CD28 affects OXSR1 expression

  • WNK1-OXSR1-STK39 pathway regulates T cell activation

  • Monitor water influx alongside OXSR1 detection

  • Examine AQP3 co-expression patterns

Cell-type specific controls and validation are essential, as OXSR1 expression and function vary significantly between tissues and cell types.

How can discrepancies in OXSR1 detection across different antibodies be reconciled?

When different OXSR1 antibodies yield inconsistent results, systematic investigation is required:

• Epitope mapping analysis:

  • Compare immunogens used to generate each antibody

  • N-terminal (AA 1-300) vs. C-terminal epitopes may show different patterns

  • Phospho-specific antibodies (pThr185) detect only activated forms

  • Some antibodies target fusion proteins while others target synthetic peptides

• Validation in knockout/knockdown systems:

  • Test each antibody in OXSR1 CRISPR knockout cells

  • Compare signal reduction in siRNA knockdown experiments

  • Use genetic models (e.g., zebrafish oxsr1a knockout) for in vivo validation

• Cross-reactivity assessment:

  • Test for recognition of related proteins (e.g., SPAK/STK39)

  • Perform peptide competition assays with immunizing peptides

  • Check reactivity against recombinant OXSR1 protein

• Application-specific optimization:

  • Some antibodies perform better in WB than in IHC or IF

  • Fixation and antigen retrieval methods affect epitope accessibility

  • Batch-to-batch variation affects reproducibility

When publishing results, clearly specify the antibody clone/catalog number and validation methods to enable proper interpretation by the scientific community.

What strategies can address non-specific binding when using OXSR1 antibodies in complex tissue samples?

Complex tissues present challenges for specific OXSR1 detection:

• Optimize blocking conditions:

  • Test different blocking agents (BSA, normal serum, commercial blockers)

  • Extend blocking time to 1-2 hours at room temperature

  • Use species-specific serum matching secondary antibody host

  • Consider adding 0.1-0.3% Triton X-100 to blocking buffer

• Refine antibody dilution and incubation:

  • Titrate antibody across broader range (1:50-1:2000)

  • Test overnight incubation at 4°C vs. shorter times at room temperature

  • For IHC, consider automated staining platforms for consistency

  • Use antibody diluents with background-reducing components

• Secondary antibody considerations:

  • Use highly cross-adsorbed secondary antibodies

  • Consider fragment (F(ab')₂) secondaries to reduce Fc receptor binding

  • Include secondary-only controls in all experiments

  • Minimize incubation time if background persists

• Tissue-specific treatments:

  • For tissues with high endogenous biotin, use biotin blocking systems

  • For tissues with high autofluorescence, employ quenching protocols

  • For fatty tissues, extend deparaffinization and use stronger detergents

  • For highly vascularized tissues, block endogenous peroxidase activity

Systematic optimization should follow a controlled, single-variable approach, documenting each modification's impact on signal-to-noise ratio.

How do post-translational modifications affect OXSR1 antibody recognition and experimental interpretation?

Post-translational modifications significantly impact OXSR1 detection and function:

• Phosphorylation effects:

  • Thr185 phosphorylation is essential for OXSR1 activation

  • Phospho-specific antibodies (pThr185) detect only the active form

  • Total OXSR1 antibodies may show reduced binding to heavily phosphorylated protein

  • In Western blots, phosphorylated forms may appear as slight mobility shifts

• Experimental manipulation of phosphorylation:

  • Lambda phosphatase treatment can confirm phospho-specificity

  • WNK kinase inhibitors reduce OXSR1 phosphorylation

  • Osmotic stress increases Thr185 phosphorylation

  • DNA damage (via ATM/ATR) induces OXSR1 phosphorylation

• Other post-translational modifications:

  • Ubiquitination may affect antibody accessibility

  • Potential SUMOylation sites might alter protein conformation

  • S-nitrosylation during oxidative stress responses

  • Complex formation with interacting proteins can mask epitopes

• Interpretation guidelines:

  • Always run parallel blots with total and phospho-specific antibodies

  • Calculate phospho/total ratios for accurate activation assessment

  • Include positive controls with known phosphorylation status

  • Consider phosphatase inhibitor effects on background signals

Understanding how these modifications affect antibody recognition is crucial for correct interpretation of experimental results, especially in stress response and kinase signaling studies.

How can OXSR1 antibodies be utilized to investigate the role of OXSR1 in infection and inflammatory diseases?

OXSR1 plays a complex role in infection responses and inflammation that can be investigated using specialized antibody-based approaches:

• Mycobacterial infection models:

  • Monitor OXSR1 upregulation in M. marinum and M. tuberculosis infections

  • Track phospho-OXSR1 status during infection progression

  • Correlate OXSR1 levels with bacterial burden quantification

  • Combine with inflammasome component detection (NLRP3, IL-1β)

• Inflammasome regulation analysis:

  • Use dual staining for OXSR1 and inflammasome markers

  • Assess OXSR1 localization during inflammasome assembly

  • Compare wild-type vs. NLRP3 inhibitor (MCC950) treated samples

  • Monitor K+ efflux alongside OXSR1 detection

• TNF-α-mediated responses:

  • Use reporter systems (e.g., TgBAC(tnfa:GFP)) with OXSR1 antibodies

  • Examine co-localization in infection foci

  • Quantify relative expression levels using image analysis

  • Compare OXSR1 knockdown effects on TNF-α production

• Human patient samples:

  • Compare OXSR1 expression/phosphorylation in disease vs. healthy tissues

  • Correlate with inflammatory markers and disease severity

  • Perform cell-type specific analysis in inflamed tissues

  • Consider genetic variants that might affect antibody recognition

This methodology has revealed that OXSR1 inhibits inflammasome activation by limiting potassium efflux, providing a mechanistic link between ion transport regulation and innate immunity.

What considerations are important when using OXSR1 antibodies to study T cell activation and immune responses?

Recent research has identified critical roles for OXSR1 in T cell biology:

• T cell activation protocols:

  • Stimulate T cells with anti-CD3/CD28 or cognate antigen

  • Track OXSR1 and phospho-OXSR1 levels during activation time course

  • Correlate with activation markers (CD69, CD25)

  • Monitor intracellular K+ and water influx alongside OXSR1 detection

• WNK1-OXSR1-STK39 pathway analysis:

  • Use co-immunoprecipitation to detect OXSR1 interactions with pathway components

  • Track sequential phosphorylation events following TCR stimulation

  • Compare effects of pathway inhibitors on T cell proliferation

  • Examine AQP3 regulation downstream of OXSR1

• Cell cycle regulation:

  • Synchronize T cells and monitor OXSR1 through cell cycle phases

  • Correlate with ATR-mediated G2/M checkpoint markers

  • Use flow cytometry with intracellular OXSR1 staining

  • Compare wild-type vs. OXSR1 knockdown effects on proliferation

• T-dependent antibody responses:

  • Examine OXSR1 in T follicular helper cell differentiation

  • Track activation-induced changes in OXSR1 localization

  • Correlate OXSR1 activity with parameters of B cell help

  • Compare germinal center responses in OXSR1-deficient models

When designing these experiments, consider that WNK1-dependent water influx through the OXSR1 pathway is required for CD4+ T cell activation, proliferation, and subsequent T-dependent antibody responses.

How can researchers optimize OXSR1 antibody-based detection in cancer tissue microarrays and pathology specimens?

Cancer tissues present unique challenges for OXSR1 detection:

• Tissue microarray optimization:

  • Use positive control cores (prostate cancer tissue shows reliable OXSR1 signal)

  • Include normal adjacent tissue for comparison

  • Perform antigen retrieval with TE buffer pH 9.0

  • Consider dual staining with tumor markers

• Heterogeneity assessment strategies:

  • Scan entire tumor section at low magnification first

  • Quantify staining intensity across different tumor regions

  • Compare tumor center vs. invasive margins

  • Correlate with hypoxia markers in serial sections

• Digital pathology approaches:

  • Use image analysis software for objective quantification

  • Develop algorithms to score OXSR1 intensity and distribution

  • Employ machine learning for pattern recognition

  • Calculate H-scores (intensity × percentage of positive cells)

• Technical considerations for archived specimens:

  • Assess fixation quality before proceeding

  • Extend antigen retrieval time for older specimens

  • Consider signal amplification systems for weak signals

  • Use multiplexed immunofluorescence for co-localization studies